HIV-1 Infection
Conditions
Brief summary
ACTG A5275 was a prospective, double-blind, randomized, placebo-controlled cross-over design pilot study evaluating the effect of atorvastatin on biomarkers of inflammation, coagulopathy, angiogenesis, and T-lymphocyte activation in HIV-1 infected individuals with suppressed HIV-1 RNA on stable protease inhibitor based antiretroviral therapy with fasting LDL cholesterol \< 130 mg/dL. Atorvastatin is a drug approved by the Food and Drug Administration (FDA) for treating high cholesterol. Atorvastatin has also been able to lower the level of inflammation blood tests in certain other diseases but has not been studied for this purpose in people who have HIV. The main goal of this experimental study is to see how taking atorvastatin affects inflammation blood tests in people infected with HIV who do not need to take medicine for high cholesterol. In addition to observing the effects of atorvastatin on the level of inflammation measured in the blood, this study evaluated if atorvastatin is safe for people with HIV who are also taking medication for HIV.
Detailed description
Since people started taking HIV medications, illness from AIDS has decreased, but other serious diseases like heart disease (heart attacks) and certain kinds of cancer have increased. HIV causes inflammation (irritation) inside the body that cannot be felt but can be measured by levels of certain inflammation blood tests. Inflammation may contribute to diseases (such as heart attacks) that have become some of the leading causes of death in people with HIV. HIV therapy can partially lower levels of inflammation measured in blood, however, levels of inflammation in people who have HIV who are taking certain kinds of anti-HIV drugs may remain high compared with those found in people not infected with HIV.
Interventions
DRUGatorvastatin
10 mg daily for 4 weeks, if no symptoms or lab findings suggestive of atorvastatin toxicity, dose increase to 20 mg daily from week 4- week 20
DRUGplacebo for atorvastin
One tablet once daily for 4 weeks. If no symptoms or lab findings suggestive of toxicity were found, then increase the dose to two tablets once daily.
Sponsors
National Institute of Allergy and Infectious Diseases (NIAID)
Pfizer
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Caregiver, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* HIV-1 infected * Combination ART that includes any boosted PI regimen for at least 6 months prior to study entry * No plans to change the antiretroviral regimen in the next year * Must have been on the same HAART regimen for at least 12 weeks with no change prior to study entry. More information on this criterion can be found in the study protocol. * If on vitamin D replacement therapy, must have been on stable regimen for ≥ 1 mo. prior to study entry. * CD4+ T-cell count obtained within 45 days prior to study entry at any laboratory that has a Clinical Laboratory Improvement Amendments (CLIA) certification or its equivalent. * Screening HIV-1 RNA \< 40 copies/mL by Abbott RealTime PCR at a laboratory certified by the DAIDS Virology Quality Assurance (VQA) program within 45 days prior to study entry. * All known HIV-1 RNA levels obtained within 180 days prior to study entry are below the limits of quantification on all tests, with documentation of at least 1 test by any FDA-approved assay at a CLIA-certified laboratory obtained between 90 to 180 days prior to study entry. A single RNA blip of \< 500 copies/mL during this time period was permissible if RNA levels immediately before and after were below the limits of quantification for the assay. * Laboratory values obtained within 45 days prior to study entry- Absolute neutrophil count (ANC) 750/mm3, Hemoglobin ≥ 9.0 g/dL for female subjects,10.0 g/dL for male subjects, Platelet count ≥ 100,000/mm3, Calculated creatinine clearance (CrCl) 30 mL/min, as estimated by the Cockcroft-Gault equation, Creatine kinase (CK) \< 3 x ULN, AST ≤ 2.0 x ULN, ALT ≤ 2.0 x ULN, Total bilirubin ≤ 2.5 x ULN. If the subject was taking an indinavir- or atazanavir-containing regimen at the time of screening, a total bilirubin of ≤ 5 x ULN is acceptable, Fasting LDL cholesterol ≥ 70 mg/dL and \< 130 mg/dL, Fasting triglycerides \< 400 mg/dL, Fasting glucose \< 110 mg/dL * Screening plasma D-dimer \> 0.34 μg/mL from a sample obtained within 45 days prior to study entry was the original D-dimer criterion. It was revised to ≥ 0.25 ug/mL four months after the first enrollment, and subsequently the D-dimer eligibility criterion was completely cut off a year later. * For females of reproductive potential (women who had not been post-menopausal for at least 24 consecutive months, i.e., who had menses within 24 months prior to study entry), or women who had not undergone surgical sterilization, specifically hysterectomy or bilateral oophorectomy or tubal ligation) required a negative serum or urine pregnancy test within 48 hours prior to entry. More information on this criterion can be found in the study protocol. * Must agree not to participate in the conception process (e.g., active attempt to become pregnant or to impregnate, sperm donation, in vitro fertilization), and if participating in sexual activity that could lead to pregnancy, the subject/partner must use at least 2 reliable methods of contraception, (condoms, without a spermicidal agent; a diaphragm or cervical cap without spermicide; an IUD; or hormone-based contraceptive), for 2 weeks before study treatment, while receiving study treatment, and for 6 weeks after receiving study treatment. As hormone-based contraceptives (oral, transdermal, or subdermal) can affect coagulopathy biomarkers, subjects who plan on using such a contraceptive during the study must be taking the same product for ≥ 4 weeks prior to screening and be encouraged to continue throughout the duration of the study if medically feasible. * Karnofsky performance score ≥ 70 on at least one occasion within 45 days prior to study entry * Confirmation of the availability of the stored pre-entry fasting plasma, serum, and cell samples. The site had to confirm that these samples had entered into the Laboratory Data Management System (LDMS).
Exclusion criteria
* Current or past malignancy (except non-melanoma cancer of the skin) * Coronary artery disease (CAD) or CAD equivalent including diabetes mellitus or National Cholesterol Education Program Adult Treatment Panel III (NCEP ATP III) calculated 10-year coronary heart disease (CHD) risk of \> 20%. * Known cirrhosis. * Known chronic active hepatitis B or C. * Thyroid-stimulating hormone (TSH) \< 1.0 x lower limit of normal or \> 1.0 x ULN. * Known inflammatory conditions, such as, but not limited to, rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), sarcoidosis, inflammatory bowel disease (IBD), chronic pancreatitis, autoimmune hepatitis, myositis, or myopathy. * Pregnant or breast-feeding. * Previous intolerance to any statin or any of its components. * Use of any lipid-lowering therapies including all statin drugs, Omega 3 fatty acids/fish oil, red yeast rice, and niacin products ≥ 1 g/day (e.g., niacin, nicotinic acid, vitamin B3) taken within 45 days prior to study entry. More information on this criterion can be found in the study protocol. * Immunosuppressant use, such as, but not limited to, systemic or potentially systemic glucocorticoids (including nasal or inhaled steroids), azathioprine, tacrolimus, mycophenolate, sirolimus, rapamycin, or cyclosporine within 45 days prior to study entry. * Use of any systemic antineoplastic or immunomodulatory treatment, investigational vaccines, interleukins, interferons, growth factors, or intravenous immunoglobulin (IVIG) within 45 days prior to study entry. More information on this criterion can be found in the study protocol. * Concurrent use of prohibited medications. More information on this criterion can be found in the study protocol. * Heavy alcohol use as defined by the National Institute on Alcohol Abuse and Alcoholism (NIAAA) (http://pubs.niaaa.nih.gov/publications/Practitioner/pocketguide/pocket\_guide3.htm) and alcohol or drug use or dependence that, in the opinion of the site investigator, would interfere with adherence to study requirements. * Current use of anticoagulation therapy other than ≤ 325 mg of daily aspirin. * Known coagulopathy, deep venous thrombosis, pulmonary embolism within 6 months prior to study entry. * Known active or recent (not fully resolved within 4 weeks prior to study entry) bacterial, fungal, parasitic, or viral infections. * Known history of recurrent rectal and/or genital herpes simplex virus (HSV) or varicella zoster virus (VZV) infection within 12 weeks prior to study entry. * Serious illness or trauma requiring systemic treatment and/or hospitalization within 4 weeks prior to study entry. * History of stroke.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Difference Between [Change From Week 24 to Week 44] and [Change From Baseline to Week 20] in log10 IL-6 | baseline, week 20, week 24, and week 44 | IL-6 (Interleukin 6) in log10 pg/mL: Difference between \[change from week 24 to week 44\] and \[change from baseline to week 20\] (i.e. \[week 44 - week 24\] - \[week 20 - baseline\]) |
| Difference Between [Change From Week 24 to Week 44] and [Change From Baseline to Week 20] in CD4+ T-cell Activation Percent | baseline, week 20, week 24, and week 44 | CD4+ T-cell activation percent (% CD38+/DR+ of CD4+): Difference between \[change from week 24 to week 44\] and \[change from baseline to week 20\] (i.e. \[week 44 - week 24\] - \[week 20 - baseline\]) |
| Difference Between [Change From Week 24 to Week 44] and [Change From Baseline to Week 20] in log10 D-dimer | baseline, week 20, week 24, and week 44 | D-dimer in log10 ng/mL: Difference between \[change from week 24 to week 44\] and \[change from baseline to week 20\] (i.e. \[week 44 - week 24\] - \[week 20 - baseline\]) |
| Difference Between [Change From Week 24 to Week 44] and [Change From Baseline to Week 20] in CD8+ T-cell Activation Percent | baseline, week 20, week 24, and week 44 | CD8+ T-cell activation percent (% CD38+/DR+ of CD8+): Difference between \[change from week 24 to week 44\] and \[change from baseline to week 20\] (i.e. \[week 44 - week 24\] - \[week 20 - baseline\]) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Difference Between [Change From Week 24 to Week 44] and Change From [Baseline to Week 20] in P-selectin (log10 Transformed) | baseline, week 20, week 24, and week 44 | P-selectin is a protein that in humans encoded by the SELP gene. P-selectin functions as a cell adhesion molecule (CAM) on the surfaces of activated endothelial cells, which line the inner surface of blood vessels, and activated platelets. Difference between \[change from week 24 to week 44\] and change from \[baseline to week 20\] is defined as \[week 44 - week 24\] - \[week 20 - baseline\]. |
| Difference Between [Change From Week 24 to Week 44] and Change From [Baseline to Week 20] in sCD163 (log10 Transformed) | baseline, week 20, week 24, and week 44 | CD163 (Cluster of Differentiation 163) is a protein that in humans encoded by the CD163 gene; and sCD163 is soluble CD163. Difference between \[change from week 24 to week 44\] and change from \[baseline to week 20\] is defined as \[week 44 - week 24\] - \[week 20 - baseline\]. |
| Difference Between [Change From Week 24 to Week 44] and Change From [Baseline to Week 20] in MCP-1 (log10 Transformed) | baseline, week 20, week 24, and week 44 | Monocyte chemoattractant protein-1 (MCP-1/CCL2) is one of the key chemokines that regulate migration and infiltration of monocytes/macrophages. Difference between \[change from week 24 to week 44\] and change from \[baseline to week 20\] is defined as \[week 44 - week 24\] - \[week 20 - baseline\]. |
| Number of Participants With Safety Endpoints After Study Treatment Cross-over (Week 24 to Week 48) | week 24 to week 48 | Safety endpoints are defined as grade ≥ 2 signs and symptoms, laboratory abnormalities, AST/ALT \> 3 X ULN, and adverse events after study treatment cross-over (week 24 to week 48). The DAIDS Adverse Event (AE) Grading Table, Version 1.0, December 2004 (Clarification, August 2009) was used for grading of AEs. |
| Number of Participants With Safety Endpoints Before Study Treatment Cross-over (Baseline to Week 24) | week 0 to week 24 | Safety endpoints are defined as grade ≥ 2 signs and symptoms, laboratory abnormalities, AST/ALT \> 3 X ULN, and adverse events prior to study treatment cross-over (baseline to week 24). The DAIDS Adverse Event (AE) Grading Table, Version 1.0, December 2004 (Clarification, August 2009) was used for grading of AEs. |
| Difference Between [Change From Week 24 to Week 44] and Change From [Baseline to Week 20] in IP-10 (log10 Transformed) | baseline, week 20, week 24, and week 44 | IFN-gamma-inducible protein 10 (IP-10 or CXCL10) is a chemokine secreted from cells stimulated with type I and II IFNs and LPS, is also a chemoattractant for activated T cells. Difference between \[change from week 24 to week 44\] and change from \[baseline to week 20\] is defined as \[week 44 - week 24\] - \[week 20 - baseline\]. |
| Difference Between [Change From Week 24 to Week 44] and Change From [Baseline to Week 20] in CD40L (log10 Transformed) | baseline, week 20, week 24, and week 44 | Cluster of differentiation 40 (CD40L) is a costimulatory protein found on antigen presenting cells and is required for their activation. Difference between \[change from week 24 to week 44\] and change from \[baseline to week 20\] is defined as \[week 44 - week 24\] - \[week 20 - baseline\]. |
| Difference Between [Change From Week 24 to Week 44] and Change From [Baseline to Week 20] in sCD14 (log10 Transformed) | baseline, week 20, week 24, and week 44 | Soluble cluster of differentiation 14 (sCD14) is a human gene. Difference between \[change from week 24 to week 44\] and change from \[baseline to week 20\] is defined as \[week 44 - week 24\] - \[week 20 - baseline\]. |
Countries
Puerto Rico, United States
Participant flow
Recruitment details
A5275 opened under version 1.0 on April 7, 2011, and the first participant was randomized on April 14, 2011. Accrual to the study closed on May 31, 2013, with a total of 98 participants enrolled at 31 sites.
Pre-assignment details
Four enrolled participants did not start study treatment (3 from arm A and 1 from arm B) due to enrollment error and noncompliance. These 4 participants were not included in the study efficacy or safety analyses.
Participants by arm
| Arm | Count |
|---|---|
| Arm A: Atorvastatin / Placebo At study entry (week 0), participants continued the entry boosted PI-based antiretroviral regimen (not provided by the study) and initiated atorvastatin at a daily dose of 10 mg for 4 weeks. If no symptoms or lab findings suggestive of atorvastatin toxicity were found, the dose of atorvastatin was increased to 20 mg daily at the week 4 visit. At week 20, atorvastatin was stopped for a 4-week washout period.
At week 24, placebo was started for 4 weeks. If no symptoms or lab findings suggestive of toxicity were found, the placebo dose was doubled at week 28. At week 44, the placebo was stopped to allow for another 4-week washout period.
atorvastatin: 10 mg daily for 4 weeks, if no symptoms or lab findings suggestive of atorvastatin toxicity, dose increase to 20 mg daily from week 4 - week 20 | 46 |
| Arm B: Placebo / Atorvastatin At study entry (week 0), participants continued the entry boosted PI-based antiretroviral regimen (not provided by the study) and initiated placebo for 4 weeks. If no symptoms or lab findings suggestive of toxicity were found, the dose of placebo was doubled at the week 4 visit. At week 20, the placebo was stopped for a 4-week washout period.
At week 24, atorvastatin was started at a daily dose of 10 mg for 4 weeks. If no symptoms or lab findings suggestive of atorvastatin toxicity were found, the dose of atorvastatin was increased to 20 mg daily at week 28. At week 44, atorvastatin was stopped to allow for another 4-week washout period.
atorvastatin: Starting at week 24, 10 mg daily for 4 weeks. If no symptoms or lab findings suggestive of atorvastatin toxicity were found, 20 mg daily from week 28- week 44. | 48 |
| Total | 94 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 |
|---|---|---|---|
| Week 0 - 20 | Lost to Follow-up | 2 | 1 |
| Week 0 - 20 | Withdrawal by Subject | 1 | 0 |
| Week 24 - 44 | Lost to Follow-up | 0 | 2 |
| Week 24 - 44 | Site closed | 0 | 1 |
| Week 24 - 44 | unable to get to clinic | 1 | 1 |
Baseline characteristics
| Characteristic | Arm A: Atorvastatin / Placebo | Arm B: Placebo / Atorvastatin | Total |
|---|---|---|---|
| Age, Continuous | 47 years | 50 years | 48 years |
| Age, Customized 18-29 Years | 3 participants | 2 participants | 5 participants |
| Age, Customized 30-39 Years | 9 participants | 6 participants | 15 participants |
| Age, Customized 40-49 Years | 16 participants | 16 participants | 32 participants |
| Age, Customized 50-59 Years | 14 participants | 21 participants | 35 participants |
| Age, Customized >=60 Years | 4 participants | 3 participants | 7 participants |
| CD4 count | 587 cells/mm^3 | 545 cells/mm^3 | 552 cells/mm^3 |
| HIV-1 RNA < assay lower limit | 46 participants | 47 participants | 93 participants |
| HIV-1 RNA >= assay lower limit | 0 participants | 1 participants | 1 participants |
| Race/Ethnicity, Customized Asian, Pacific Islander | 1 participants | 0 participants | 1 participants |
| Race/Ethnicity, Customized Black non-Hispanic | 21 participants | 22 participants | 43 participants |
| Race/Ethnicity, Customized Hispanic (regardless of race) | 14 participants | 13 participants | 27 participants |
| Race/Ethnicity, Customized White non-Hispanic | 10 participants | 13 participants | 23 participants |
| Region of Enrollment United States | 46 participants | 48 participants | 94 participants |
| Sex: Female, Male Female | 17 Participants | 13 Participants | 30 Participants |
| Sex: Female, Male Male | 29 Participants | 35 Participants | 64 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk | EG003 affected / at risk |
|---|---|---|---|---|
| deaths Total, all-cause mortality | — / — | — / — | — / — | — / — |
| other Total, other adverse events | 37 / 46 | 44 / 48 | 30 / 41 | 31 / 43 |
| serious Total, serious adverse events | 4 / 46 | 3 / 48 | 0 / 41 | 0 / 43 |
Outcome results
Primary
Difference Between [Change From Week 24 to Week 44] and [Change From Baseline to Week 20] in CD4+ T-cell Activation Percent
CD4+ T-cell activation percent (% CD38+/DR+ of CD4+): Difference between \[change from week 24 to week 44\] and \[change from baseline to week 20\] (i.e. \[week 44 - week 24\] - \[week 20 - baseline\])
Time frame: baseline, week 20, week 24, and week 44
Population: The primary analysis was as-treated, limited to participants who had data for baseline, week 20, week 24, and week 44, and remained on study treatment through week 44 (allowing treatment interruption \< 4 weeks), and did not use prohibited medications or have virologic failure during the course of the study.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Arm A: Atorvastatin / Placebo | Difference Between [Change From Week 24 to Week 44] and [Change From Baseline to Week 20] in CD4+ T-cell Activation Percent | -0.20 percent |
| Arm B: Placebo / Atorvastatin | Difference Between [Change From Week 24 to Week 44] and [Change From Baseline to Week 20] in CD4+ T-cell Activation Percent | 0.60 percent |
Comparison: The null hypothesis is that there is no difference between arm A and arm B in the differences of the changes (\[week 44 - week 24\] - \[week 20 - baseline\]) in CD4+ T-cell activation percent (% CD38+/DR+ of CD4)p-value: 0.495Wilcoxon (Mann-Whitney)
Primary
Difference Between [Change From Week 24 to Week 44] and [Change From Baseline to Week 20] in CD8+ T-cell Activation Percent
CD8+ T-cell activation percent (% CD38+/DR+ of CD8+): Difference between \[change from week 24 to week 44\] and \[change from baseline to week 20\] (i.e. \[week 44 - week 24\] - \[week 20 - baseline\])
Time frame: baseline, week 20, week 24, and week 44
Population: The primary analysis was as-treated, limited to participants who had data for baseline, week 20, week 24, and week 44, and remained on study treatment through week 44 (allowing treatment interruption \< 4 weeks), and did not use prohibited medications or have virologic failure during the course of the study.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Arm A: Atorvastatin / Placebo | Difference Between [Change From Week 24 to Week 44] and [Change From Baseline to Week 20] in CD8+ T-cell Activation Percent | 1.10 percent |
| Arm B: Placebo / Atorvastatin | Difference Between [Change From Week 24 to Week 44] and [Change From Baseline to Week 20] in CD8+ T-cell Activation Percent | -1.15 percent |
Comparison: The null hypothesis is that there is no difference between arm A and arm B in the differences of the changes (\[week 44 - week 24\] - \[week 20 - baseline\]) in CD8+ T-cell activation percent (% CD38+/DR+ of CD8+)p-value: 0.508Wilcoxon (Mann-Whitney)
Primary
Difference Between [Change From Week 24 to Week 44] and [Change From Baseline to Week 20] in log10 D-dimer
D-dimer in log10 ng/mL: Difference between \[change from week 24 to week 44\] and \[change from baseline to week 20\] (i.e. \[week 44 - week 24\] - \[week 20 - baseline\])
Time frame: baseline, week 20, week 24, and week 44
Population: The primary analysis was as-treated, limited to participants who had data for baseline, week 20, week 24, and week 44, and remained on study treatment through week 44 (allowing treatment interruption \< 4 weeks), and did not use prohibited medications or have virologic failure during the course of the study.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Arm A: Atorvastatin / Placebo | Difference Between [Change From Week 24 to Week 44] and [Change From Baseline to Week 20] in log10 D-dimer | -0.02 log10 ng/mL |
| Arm B: Placebo / Atorvastatin | Difference Between [Change From Week 24 to Week 44] and [Change From Baseline to Week 20] in log10 D-dimer | 0.00 log10 ng/mL |
Comparison: The null hypothesis is that there is no difference between arm A and arm B in the differences of the changes (\[week 44 - week 24\] - \[week 20 - baseline\]) in log10 D-dimerp-value: 0.704Wilcoxon (Mann-Whitney)
Primary
Difference Between [Change From Week 24 to Week 44] and [Change From Baseline to Week 20] in log10 IL-6
IL-6 (Interleukin 6) in log10 pg/mL: Difference between \[change from week 24 to week 44\] and \[change from baseline to week 20\] (i.e. \[week 44 - week 24\] - \[week 20 - baseline\])
Time frame: baseline, week 20, week 24, and week 44
Population: The primary analysis was as-treated, limited to participants who had data for baseline, week 20, week 24, and week 44, and remained on study treatment through week 44 (allowing treatment interruption \< 4 weeks), and did not use prohibited medications or have virologic failure during the course of the study.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Arm A: Atorvastatin / Placebo | Difference Between [Change From Week 24 to Week 44] and [Change From Baseline to Week 20] in log10 IL-6 | -0.08 log10 pg/mL |
| Arm B: Placebo / Atorvastatin | Difference Between [Change From Week 24 to Week 44] and [Change From Baseline to Week 20] in log10 IL-6 | -0.08 log10 pg/mL |
Comparison: The null hypothesis is that there is no difference between arm A and arm B in the differences of the changes (\[week 44 - week 24\] - \[week 20 - baseline\]) in log10 IL-6p-value: 0.94Wilcoxon (Mann-Whitney)
Secondary
Difference Between [Change From Week 24 to Week 44] and Change From [Baseline to Week 20] in CD40L (log10 Transformed)
Cluster of differentiation 40 (CD40L) is a costimulatory protein found on antigen presenting cells and is required for their activation. Difference between \[change from week 24 to week 44\] and change from \[baseline to week 20\] is defined as \[week 44 - week 24\] - \[week 20 - baseline\].
Time frame: baseline, week 20, week 24, and week 44
Population: This analysis was as-treated, limited to participants who had data for baseline, week 20, week 24, and week 44, and remained on study treatment through week 44 (allowing treatment interruption \< 4 weeks), and did not use prohibited medications or have virologic failure during the course of the study.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Arm A: Atorvastatin / Placebo | Difference Between [Change From Week 24 to Week 44] and Change From [Baseline to Week 20] in CD40L (log10 Transformed) | 0.01 log10 pg/ml |
| Arm B: Placebo / Atorvastatin | Difference Between [Change From Week 24 to Week 44] and Change From [Baseline to Week 20] in CD40L (log10 Transformed) | -0.03 log10 pg/ml |
Secondary
Difference Between [Change From Week 24 to Week 44] and Change From [Baseline to Week 20] in IP-10 (log10 Transformed)
IFN-gamma-inducible protein 10 (IP-10 or CXCL10) is a chemokine secreted from cells stimulated with type I and II IFNs and LPS, is also a chemoattractant for activated T cells. Difference between \[change from week 24 to week 44\] and change from \[baseline to week 20\] is defined as \[week 44 - week 24\] - \[week 20 - baseline\].
Time frame: baseline, week 20, week 24, and week 44
Population: This analysis was as-treated, limited to participants who had data for baseline, week 20, week 24, and week 44, and remained on study treatment through week 44 (allowing treatment interruption \< 4 weeks), and did not use prohibited medications or have virologic failure during the course of the study.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Arm A: Atorvastatin / Placebo | Difference Between [Change From Week 24 to Week 44] and Change From [Baseline to Week 20] in IP-10 (log10 Transformed) | -0.03 log10 pg/ml |
| Arm B: Placebo / Atorvastatin | Difference Between [Change From Week 24 to Week 44] and Change From [Baseline to Week 20] in IP-10 (log10 Transformed) | -0.04 log10 pg/ml |
Secondary
Difference Between [Change From Week 24 to Week 44] and Change From [Baseline to Week 20] in MCP-1 (log10 Transformed)
Monocyte chemoattractant protein-1 (MCP-1/CCL2) is one of the key chemokines that regulate migration and infiltration of monocytes/macrophages. Difference between \[change from week 24 to week 44\] and change from \[baseline to week 20\] is defined as \[week 44 - week 24\] - \[week 20 - baseline\].
Time frame: baseline, week 20, week 24, and week 44
Population: This analysis was as-treated, limited to participants who had data for baseline, week 20, week 24, and week 44, and remained on study treatment through week 44 (allowing treatment interruption \< 4 weeks), and did not use prohibited medications or have virologic failure during the course of the study.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Arm A: Atorvastatin / Placebo | Difference Between [Change From Week 24 to Week 44] and Change From [Baseline to Week 20] in MCP-1 (log10 Transformed) | 0.03 log10 pg/ml |
| Arm B: Placebo / Atorvastatin | Difference Between [Change From Week 24 to Week 44] and Change From [Baseline to Week 20] in MCP-1 (log10 Transformed) | -0.04 log10 pg/ml |
Secondary
Difference Between [Change From Week 24 to Week 44] and Change From [Baseline to Week 20] in P-selectin (log10 Transformed)
P-selectin is a protein that in humans encoded by the SELP gene. P-selectin functions as a cell adhesion molecule (CAM) on the surfaces of activated endothelial cells, which line the inner surface of blood vessels, and activated platelets. Difference between \[change from week 24 to week 44\] and change from \[baseline to week 20\] is defined as \[week 44 - week 24\] - \[week 20 - baseline\].
Time frame: baseline, week 20, week 24, and week 44
Population: This analysis was as-treated, limited to participants who had data for baseline, week 20, week 24, and week 44, and remained on study treatment through week 44 (allowing treatment interruption \< 4 weeks), and did not use prohibited medications or have virologic failure during the course of the study.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Arm A: Atorvastatin / Placebo | Difference Between [Change From Week 24 to Week 44] and Change From [Baseline to Week 20] in P-selectin (log10 Transformed) | 0.01 log10 ng/ml |
| Arm B: Placebo / Atorvastatin | Difference Between [Change From Week 24 to Week 44] and Change From [Baseline to Week 20] in P-selectin (log10 Transformed) | -0.06 log10 ng/ml |
Secondary
Difference Between [Change From Week 24 to Week 44] and Change From [Baseline to Week 20] in sCD14 (log10 Transformed)
Soluble cluster of differentiation 14 (sCD14) is a human gene. Difference between \[change from week 24 to week 44\] and change from \[baseline to week 20\] is defined as \[week 44 - week 24\] - \[week 20 - baseline\].
Time frame: baseline, week 20, week 24, and week 44
Population: This analysis was as-treated, limited to participants who had data for baseline, week 20, week 24, and week 44, and remained on study treatment through week 44 (allowing treatment interruption \< 4 weeks), and did not use prohibited medications or have virologic failure during the course of the study.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Arm A: Atorvastatin / Placebo | Difference Between [Change From Week 24 to Week 44] and Change From [Baseline to Week 20] in sCD14 (log10 Transformed) | 0.00 log10 ng/ml |
| Arm B: Placebo / Atorvastatin | Difference Between [Change From Week 24 to Week 44] and Change From [Baseline to Week 20] in sCD14 (log10 Transformed) | 0.00 log10 ng/ml |
Secondary
Difference Between [Change From Week 24 to Week 44] and Change From [Baseline to Week 20] in sCD163 (log10 Transformed)
CD163 (Cluster of Differentiation 163) is a protein that in humans encoded by the CD163 gene; and sCD163 is soluble CD163. Difference between \[change from week 24 to week 44\] and change from \[baseline to week 20\] is defined as \[week 44 - week 24\] - \[week 20 - baseline\].
Time frame: baseline, week 20, week 24, and week 44
Population: This analysis was as-treated, limited to participants who had data for baseline, week 20, week 24, and week 44, and remained on study treatment through week 44 (allowing treatment interruption \< 4 weeks), and did not use prohibited medications or have virologic failure during the course of the study.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Arm A: Atorvastatin / Placebo | Difference Between [Change From Week 24 to Week 44] and Change From [Baseline to Week 20] in sCD163 (log10 Transformed) | -0.04 log10 ng/ml |
| Arm B: Placebo / Atorvastatin | Difference Between [Change From Week 24 to Week 44] and Change From [Baseline to Week 20] in sCD163 (log10 Transformed) | 0.03 log10 ng/ml |
Secondary
Number of Participants With Safety Endpoints After Study Treatment Cross-over (Week 24 to Week 48)
Safety endpoints are defined as grade ≥ 2 signs and symptoms, laboratory abnormalities, AST/ALT \> 3 X ULN, and adverse events after study treatment cross-over (week 24 to week 48). The DAIDS Adverse Event (AE) Grading Table, Version 1.0, December 2004 (Clarification, August 2009) was used for grading of AEs.
Time frame: week 24 to week 48
Population: participants who crossed over study treatment at week 24
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Arm A: Atorvastatin / Placebo | Number of Participants With Safety Endpoints After Study Treatment Cross-over (Week 24 to Week 48) | 20 participants |
| Arm B: Placebo / Atorvastatin | Number of Participants With Safety Endpoints After Study Treatment Cross-over (Week 24 to Week 48) | 14 participants |
Secondary
Number of Participants With Safety Endpoints Before Study Treatment Cross-over (Baseline to Week 24)
Safety endpoints are defined as grade ≥ 2 signs and symptoms, laboratory abnormalities, AST/ALT \> 3 X ULN, and adverse events prior to study treatment cross-over (baseline to week 24). The DAIDS Adverse Event (AE) Grading Table, Version 1.0, December 2004 (Clarification, August 2009) was used for grading of AEs.
Time frame: week 0 to week 24
Population: participants who started study treatment
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Arm A: Atorvastatin / Placebo | Number of Participants With Safety Endpoints Before Study Treatment Cross-over (Baseline to Week 24) | 20 participants |
| Arm B: Placebo / Atorvastatin | Number of Participants With Safety Endpoints Before Study Treatment Cross-over (Baseline to Week 24) | 22 participants |